Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity.

Annika Rössler Janine KimpelVerena FleischerSilke Huber Dorothee von Laer Wegene Borena Reinhard Würznernull null

Published in: The Journal of infectious diseases (2022)

We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.

Keyphrases

coronavirus disease
respiratory syndrome coronavirus
dna damage
atomic force microscopy
sars cov
mass spectrometry
oxidative stress
saccharomyces cerevisiae
aqueous solution